(via NewsDirect)
Hallas explained the company offers a variety of products aimed at maintaining animal health and treating diseases, particularly respiratory and intestinal issues. While a significant portion of its revenue is attributed to its flagship product, Aivlosin, he said the company maintains a diversified portfolio with operations in over 70 countries, more than 20 products, and around 200 licences for different indications.
Hallas highlighted the company's fourth-quarter and full-year 2024 trading performance, driven by increasing demand for its products, especially Aivlosin, which assists in raising healthy animals to meet the global protein demand. The company's growth is notably robust in
Hallas clarified that the company's operations and revenue are not overly dependent on
The company is also expanding its product line with the upcoming launch of vaccine products in 2025, following recent trademark approvals in the EU,
Contact Details
+44 20 7989 0813
uk@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source